Refer to the Department of Neurology’s clinical trial page for a comprehensive listing.
About participating
What is a clinical trial? Clinical trials are organized experiments performed on human participants to determine the best way to treat, diagnose or prevent a disease. The information that scientists learn from clinical trials helps to improve the medical care for future patients. Clinical studies are carefully and ethically designed to protect participants from unnecessary side effects and other risks. Most clinical research is federally regulated with built-in safeguards to protect the participants.
- Conditions: Myositis Interventions: Drug: PF-06823859; Drug: Placebo Sponsors: Pfizer Recruiting
- Conditions: Active Idiopathic Inflammatory Myopathy; Myositis; Dermatomyositis; Polymyositis; Immune-Mediated Necrotizing Myopathy; Antisynthetase Syndrome Interventions: Biological: EFG PH20 SC; Other: PBO Sponsors: argenx Recruiting
- Conditions: Sporadic Inclusion Body Myositis; Inclusion Body Myositis Sponsors: University of California, Irvine; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Active, not recruiting
- Conditions: Rheumatoid Arthritis (RA); Systemic Lupus Erythematosus (SLE); Pemphigus Vulgaris; Multiple Sclerosis (MS); Systemic Sclerosis (SSc); Pediatric SLE; Juvenile Idiopathic Arthritis (JIA); Juvenile Dermatomyositis (JDM); Pediatric-Onset Multiple Sclerosis (POMS) Interventions: Biological: Moderna mRNA-1273; Biological: BNT162b2; Biological: Ad26.COV2.S; Drug: Continue IS (MMF or MPA); Drug: Continue IS (MTX); Biological: Continue IS (B cell depletion therapy); Biological: Monovalent [B.1.351] CoV2 preS dTM-AS03; Drug: Withhold IS (MMF or MPA); Drug: Withhold IS (MTX); Drug: Withhold IS (B cell depletion therapy); Biological: Moderna mRNA-1273, Bivalent; Biological: BNT162b2, Bivalent Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Autoimmunity Centers of Excellence; Rho Federal Systems […]
- Conditions: Muscular Dystrophy, Duchenne Interventions: Genetic: delandistrogene moxeparvovec Sponsors: Sarepta Therapeutics, Inc.; Hoffmann-La Roche Enrolling by invitation
- Conditions: Duchenne Muscular Dystrophy Interventions: Drug: Pamrevlumab Sponsors: FibroGen Terminated
- Conditions: Amyotrophic Lateral Sclerosis Interventions: Drug: ION363; Drug: Placebo Sponsors: Ionis Pharmaceuticals, Inc. Recruiting
- Conditions: Frontotemporal Lobar Degeneration (FTLD); Progressive Supranuclear Palsy (PSP); Corticobasal Degeneration (CBD); Behavioral Variant Frontotemporal Dementia (bvFTD); Semantic Variant Primary Progressive Aphasia (svPPA); Nonfluent Variant Primary Progressive Aphasia (nfvPPA); FTD With Amyotrophic Lateral Sclerosis (FTD/ALS); Amyotrophic Lateral Sclerosis; Oligosymptomatic PSP (oPSP); C9orf72; GRN Related Frontotemporal Dementia; MAPT Gene Mutation; TBK1 Gene Mutation; Oligosymptomatic Progressive Supranuclear Palsy Sponsors: Mayo Clinic; University of California, San Francisco; National Institute on Aging (NIA); National Institute of Neurological Disorders and Stroke (NINDS) Recruiting
- Conditions: Amyotrophic Lateral Sclerosis; Lou Gehrig's Disease Interventions: Drug: coenzyme Q10; Drug: Placebo Sponsors: Columbia University; National Institute of Neurological Disorders and Stroke (NINDS) Completed
- Conditions: Active Idiopathic Inflammatory Myopathy; Myositis; Dermatomyositis; Polymyositis; Immune-Mediated Necrotizing Myopathy; Antisynthetase Syndrome Interventions: Biological: EFG PH20 SC; Other: PBO Sponsors: argenx Recruiting
- Conditions: Sporadic Inclusion Body Myositis; Inclusion Body Myositis Sponsors: University of California, Irvine; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Active, not recruiting